Cvs Health Corporation CVS
Revenue Intelligence Report • 53 quarters of SEC filing data • Updated 2026-03-15
Revenue is driven by SG&A spending leverage, with $1 of SG&A generating about $6.63 of long-run revenue. The model is linear and trained on 53 quarters; holdout accuracy is solid at 2.2% MAPE, with a forecast of $79B versus actual $81B. Latest quarterly revenue stands at about $80.6B, and the FY forecast is roughly $332B, up 10.9% year over year. R&D data is not available, but the outlook appears constructive given the strong revenue trajectory and efficient SG&A ROI, though sustainability will hinge on continued efficiency and product/mix dynamics.
Investment Thesis
Our ARDL model tracks Cvs Health Corporation's revenue with exceptional precision (2.2% MAPE), indicating highly predictable cash flows. Each $1 of SG&A spending generates $6.63 in revenue, reflecting strong commercial efficiency.
Revenue Forecast
Quarterly Detail
| Quarter | Model Forecast | Actual | 95% Range | YoY Growth | Status |
|---|---|---|---|---|---|
| Q2 2022 | $79B | $81B | $76B – $81B | +17.6% | ✓ In range |
| Q3 2022 | $80B | $76B – $83B | +15.3% | ||
| Q4 2022 | $82B | $78B – $86B | +12.6% | ||
| Q2 2023 | $84B | $79B – $89B | +9.5% | ||
| Q3 2023 | $86B | $81B – $92B | +7.0% |
How Spending Drives Revenue
Want this analysis for your portfolio?
I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.
Get in Touch